Literature DB >> 1705551

Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin.

D A Owensby1, P A Morton, T C Wun, A L Schwartz.   

Abstract

Catabolism of plasminogen activators by Hep G2 cells is mediated by a specific receptor which recognizes complexes of these serine proteases with their physiological inhibitor, plasminogen activator inhibitor type-1 (PAI-1). This catabolic process is initiated by interaction of exogenous plasminogen activators with bioactive PAI-1, which is secreted and localizes in an active form to the extracellular matrix (ECM) of Hep G2 cells. We now report that vitronectin (VN) mediates the specific binding of PAI-1 to the ECM of these cells. Purified bovine or human VN competes for specific binding of PAI-1 to Hep G2 ECM, and ligand blotting reveals specific binding of PAI-1 to ECM-associated VN. Hep G2 cells secrete both VN and PAI-1, and pulse-chase studies strongly suggest that these proteins associate only following secretion. Although Hep G2 cell-derived VN does not significantly bind to ECM in vitro, 30-40% of endogenous PAI-1 binds to the ECM, even in the presence of human serum, suggesting that ECM-associated VN is entirely derived from bovine serum. PAI-1 was localized by indirect immunofluorescence to ECM beneath cells and at cell margins, whereas VN exhibited a uniform distribution throughout the growth substratum. VN associated with the ECM may confer retention and bioactivity to PAI-1, potentially facilitating both pericellular regulation of plasmin generation and the rapid hepatic clearance of plasminogen activators.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705551

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

2.  Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells.

Authors:  J Hagège; M N Peraldi; E Rondeau; C Adida; F Delarue; R Medcalf; W D Schleuning; J D Sraer
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

3.  Bombyx batryticatus Cocoonase Inhibitor Separation, Purification, and Inhibitory Effect on the Proliferation of SMCC-7721 HeLa-Derived Cells.

Authors:  Houwei Wang; Lingchuan Xu; Yanling Dou; Jiachao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-14       Impact factor: 2.650

4.  Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary atherosclerotic lesions involved in acute myocardial infarction.

Authors:  K Yorimitsu; T Saito; T Toyozaki; T Ishide; N Ohnuma; Y Inagaki
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

5.  Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.

Authors:  G Bu; S Williams; D K Strickland; A L Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 6.  Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.

Authors:  Xiaomin Deng; James P Luyendyk; Patricia E Ganey; Robert A Roth
Journal:  Pharmacol Rev       Date:  2009-09       Impact factor: 25.468

Review 7.  Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

Authors:  M Yamamoto; R Sawaya; S Mohanam; V H Rao; J M Bruner; G L Nicolson; K Ohshima; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer.

Authors:  Yaakov Bentov; Theodore J Brown; Mohammad R Akbari; Robert Royer; Harvey Risch; Barry Rosen; John McLaughlin; Ping Sun; Shiyu Zhang; Steven A Narod; Robert F Casper
Journal:  PLoS One       Date:  2009-06-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.